Comparative effectiveness of statins, metformin, and vitamin D, for prevention of preeclampsia: a systematic review and network meta-analysis of randomized trials
El-Khouly MA, Mahgoub MM, Abd-Elkareem ME, El-Bayaa NM, Farouk JM, Fouad MM, Salah HM, Saad AK, Al-Azab M, Mohamed RA, Dahshan K, Abouda DA
BMC pregnancy and childbirth · 0 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2026-10-02 · BMC Pregnancy Childbirth · vol. 26 · número 1
- Editorial
- BioMed Central
- Citado
- 0 citas · más que el 73% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 0 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Pregnancy and preeclampsia studies · Neurological Complications and Syndromes · Gestational Diabetes Research and Management
- Palabras clave
- preeclampsia prevention, statins, metformin, vitamin D supplementation, high-risk pregnancy, gestational hypertension, preterm birth, low birth weight, perinatal outcomes, gestational diabetes mellitus, omega-3 fatty acids, dose comparison, SUCRA ranking, maternal and neonatal morbidity, drug safety in pregnancy
- MeSH
- humans, pre-eclampsia, metformin, vitamin d, hydroxymethylglutaryl-coa reductase inhibitors, pregnancy outcome, pregnancy, infant, newborn, female, randomized controlled trials as topic
12 autores
- Menna Alaa El-Khouly🇪🇬Port Said University
- Mazen Mohammed Mahgoub🇪🇬Port Said University
- Mahmoud E. Abd-Elkareem🇪🇬 · autor de correspondenciaPort Said University
- Noreen M. El-Bayaa🇪🇬Port Said University
- Jana Mohamed Farouk🇪🇬Port Said University
- Mariam M. Fouad🇪🇬Port Said University
- Habiba Mohammed Salah🇪🇬Beni-Suef University
- Ahmed Khaled Saad🇪🇬Beni-Suef University
- Mohammed Al-azab🇾🇪Sana'a University
- Rofida Ayman Mohamed🇪🇬Beni-Suef University
- Kholoud Dahshan🇪🇬Beni-Suef University
- Dalia Atef Abouda🇪🇬Alexandria University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality worldwide, yet effective pharmacological preventive strategies remain uncertain. Statins, metformin, and vitamin D, alone or combined with omega-3, have been investigated for potential protective effects, but comparative evidence is limited.
Objective
To compare the effectiveness of statins, metformin, and vitamin D in preventing preeclampsia and related adverse outcomes among high-risk pregnant women.
Methods
A systematic review and network meta-analysis of randomized controlled trials was conducted. PubMed, Scopus, Web of Science, Cochrane, and Epistemonikos were searched from September 11, 2020, to September 11, 2025. Eight trials involving 4,078 high-risk pregnant women were included. Participants were randomized to statins, metformin, or vitamin D at different doses versus placebo. The primary outcome was the incidence of preeclampsia. Secondary outcomes included gestational hypertension, preterm birth, low birth weight, neonatal intensive care unit admission, gestational diabetes, respiratory distress syndrome, and perinatal outcomes. Risk ratios with 95% confidence intervals were calculated, and interventions were ranked using the surface under the cumulative ranking probabilities.
Results
Eight randomized controlled trials were analyzed. Compared with placebo, higher-dose vitamin D supplementation showed associations with lower estimated risks of preeclampsia, particularly vitamin D 4,000 IU/day (risk ratio 0.21, 95% confidence interval 0.06-0.72) and 60,000 IU monthly (risk ratio 0.36, 95% confidence interval 0.19-0.70). These relative effects corresponded to approximate absolute risk differences of 8% and 6%, respectively, based on observed baseline risks, and reflect associations rather than proven causality. Estimates were derived from limited direct evidence within sparse networks. These dose-specific vitamin D regimens had the highest probabilistic ranking for preeclampsia within the network, but these rankings should be interpreted as exploratory rather than definitive. Higher-dose vitamin D was also associated with trends toward lower event rates of preterm births and low-birth-weight infants, although estimates were imprecise. Evidence for statins and metformin was inconsistent, with wide confidence intervals. SUCRA rankings suggested vitamin D as the highest relative ranking probability overall intervention within the network, followed by statins; however, these rankings remain exploratory given the limited network structure. These associations were derived from limited direct evidence within sparse networks and should be interpreted cautiously. Probabilistic rankings and SUCRA values reflect relative positioning within the network rather than comparative effectiveness.
Conclusion
In high-risk pregnancies, higher-dose vitamin D regimens were associated with lower estimated risks of preeclampsia compared with placebo; however, these findings are based on limited, heterogeneous, and partly indirect evidence from sparse networks. The certainty of evidence is low, and the observed effect sizes should not be interpreted as evidence of clinical effectiveness. These findings are best considered hypothesis-generating and are intended to inform the design of future studies rather than guide clinical practice. Evidence for statins and metformin remains limited and inconsistent. Overall, further large, well-designed randomized trials are required before firm clinical recommendations can be made.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.